DNA · Ginkgo Bioworks Holdings, Inc.

Summary

Ginkgo Bioworks Holdings, Inc. announced that its wholly owned subsidiary, Ginkgo Bioworks, Inc., entered into a Stock Purchase Agreement dated February 26, 2026, with Tower Biosecurity, Inc. to contribute all equity interests in Ginkgo Biosecurity, LLC, representing substantially all of the Company's Biosecurity segment operations, in exchange for approximately 20% of Tower Biosecurity's issued and outstanding equity on a fully diluted basis.

Key takeaways

• On February 26, 2026, Ginkgo Bioworks, Inc. (Seller) entered into Stock Purchase Agreement with Tower Biosecurity, Inc. (Purchaser) and Ginkgo Biosecurity, LLC (Biosecurity).
• Seller to contribute all issued and outstanding equity interests of Biosecurity, constituting substantially all of Company's Biosecurity segment operations.
• Purchaser to issue shares of its common stock representing approximately 20% of issued and outstanding equity on fully diluted basis.
• Transaction expected to complete in first half of 2026, subject to customary closing conditions.
• Agreement filed as Exhibit 1.1.